findmyKOL

Petros Karakousis, MD

Basic profile

Johns Hopkins University

ORCIDNPI
RegionBaltimore, MD · NortheastSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPaymentsNone reportedNIH funding2005–2026Why? →

Petros Karakousis is an Infectious Disease physician affiliated with Johns Hopkins University. OpenAlex indexes 263 publications with 7,215 citations (h-index 46); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
263publications

Distinct works indexed by OpenAlex, matched via ORCID.

7,215citations

Total citations across indexed works.

46h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
14NIH grants · 2005–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

600 N Wolfe St
Baltimore, MD 212870005

Telephone

410-955-1725

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    40.3%
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor19.4%
    Triumeq53%Descovy47%
    Part D<11 patients
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor14.3%
    Tivicay100%
    Part D12 patients

    + 1 more class in this area

  • Cardiovascular

    38.6%
    Statin18.6%
    Atorvastatin Calcium100%
    Part D13 patients
    Calcium channel blocker6.9%
    Amlodipine Besylate54%Nifedipine Er46%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    9.4%
    DPP-4 inhibitor6.3%
    Januvia100%
    Part D<11 patients
    GLP-1 receptor agonist3.1%
    Rybelsus100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

14 NIH research awards on record, funded 20052026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”